新一轮集采后冠脉“硬通货”大降价！近万元药物球囊普降至两千多元

Core Viewpoint - The introduction of centralized procurement for coronary stents has significantly increased the usage of drug-coated balloons (DCBs), marking a shift towards a more affordable era for high-value medical consumables in public hospitals' cardiology departments [1][4]. Group 1: Market Dynamics - After the sixth round of centralized procurement, the prices of DCBs have drastically decreased, with some products dropping from over 10,000 yuan to around 2,000 yuan, indicating a major price reduction trend [1][3]. - The average annual growth rate of DCB usage has exceeded 25% since the implementation of coronary stent centralized procurement [1][3]. - Approximately 30% of percutaneous coronary intervention (PCI) procedures utilize DCBs, with nearly 200,000 PCI procedures performed annually in China [3]. Group 2: Market Size and Competition - Despite the increase in DCB usage, the overall market size may shrink due to significant price reductions; for instance, if the average price is 2,500 yuan with an annual usage of 1 million, the market size would be around 2.5 billion yuan, down from an estimated 3 billion yuan [4]. - The market for coronary DCBs is becoming increasingly competitive, with over 20 manufacturers vying for market share at similar price points, which raises the bar for cost control and operational efficiency [4][5]. - The domestic manufacturers are now dominating the DCB market, with the top three companies holding nearly 48% market share, breaking the previous dominance of foreign giants [4]. Group 3: Future Outlook - The overall demand for DCBs is expected to continue rising, with projections indicating that usage could exceed 2 million by 2030, primarily driven by coronary DCBs [3]. - Companies that previously relied heavily on coronary products for growth will face significant challenges in finding new growth drivers following the inclusion of both coronary stents and DCBs in national centralized procurement [4][5].